Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
 Phase of development
 Approved
 Pre-registration & Phase III
 Phase II & Phase II/III

 Type of molecule
 Cell and gene therapies
 Monoclonal antibodies
 Proteins
 Peptides (recombinant)
 Vaccines
 Others

 Target therapeutic area
 Autoimmune disorders
 Blood disorders
 Bone disorders
 Genetic disorders
 Metabolic disorders
 Neurological disorders
 Oncological disorders
 Respiratory disorders
 Others

 Type of drug delivery system
 Large volume wearable injectors
 Autoinjectors
 Prefilled syringes
 Needle-free injectors
 Drug reconstitution systems

To Request for sample - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics. To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:  Phase of development  Approved  Pre-registration & Phase III  Phase II & Phase II/III  Type of molecule  Cell and gene therapies  Monoclonal antibodies  Proteins  Peptides (recombinant)  Vaccines  Others  Target therapeutic area  Autoimmune disorders  Blood disorders  Bone disorders  Genetic disorders  Metabolic disorders  Neurological disorders  Oncological disorders  Respiratory disorders  Others  Type of drug delivery system  Large volume wearable injectors  Autoinjectors  Prefilled syringes  Needle-free injectors  Drug reconstitution systems To Request for sample - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
WWW.ROOTSANALYSIS.COM
Subcutaneous Biologics, Technologies and Drug Delivery Systems | Industry Analysis | Market Size | 2030
Market research report on subcutaneous biologics, technologies and drug delivery systems with focus on current market landscape and 2030 market size
0 Comments 0 Shares